CoChat

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Open access
Wang, Yao, Chen, Meixia, Wu, Zhiqiang, Tong, Chuan, Dai, Hanren, Guo, Yelei, Liu, Yang, Huang, Jianhua, Lv, Haiyan, Luo, Can, Feng, Kai-chao, Yang, Qing-ming, Li, Xiao-lei, Han, Weidong · 2018 · OncoImmunology

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor specificity and the postulated toxicities of CART-133 were first assessed. Then, we conducted a phase I clinical study in which patients with advanced and CD133-positive tumors received CART-133 cell-infusion. We enrolled 23 patients (14 with hepatocellular carcinoma [HCC], 7 with pancreatic carcinomas, and 2 with colorectal carcinomas). The 8 initially enrolled patients with HCC were treated by a CART-133 cell dose escalation scheme (0.05–2 × 106/kg). The higher CAR-copy numbers and its reverse relationship with the count of CD133+ cells in peripheral blood led to the determination of an acceptable cell dose is 0.5–2 × 106/kg and reinfusion cycle in 23 patients. The primary toxicity is a decrease in hemoglobin/platelet (≤ grade 3) that is self-recovered within 1 week. Of 23 patients, three achieved partial remission, and 14 achieved stable disease. The 3-month disease control rate was 65.2%, and the median progression-free survival was 5 months. Repeated cell infusions seemed to provide a longer period of disease stability, especially in patients who achieved tumor reduction after the first cell-infusion. 21 out of 23 patients had not developed detectable de novo lesions during this term. Analysis of biopsied tissues by immunohistochemistry showed CD133+ cells were eliminated after CART-133 infusions. This trial showed the feasibility, controllable toxicities, and effective activity of CART-133 transfer for treating patients with CD133-postive and late-stage metastasis malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2018.1440169

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Treatment plan and treatment protocol. (A) Schematic representation of the CAR-133-CD137ζ chimeric T-cell receptor cDNA plasmid, not to scale. (B) Consort flow diagram of the clinical trial. (C) One standard cycle of CART-133 treatment procedure. CART-133 treatment for non-HCC patients included a chemotherapy pre-regimen (red dashed line).
Figure 1. Treatment plan and treatment protocol. (A) Schematic representation of the CAR-133-CD137ζ chimeric T-cell receptor cDNA plasmid, not to scale. (B) Consort flow diagram of the clinical trial. (C) One standard cycle of CART-133 treatment procedure. CART-133 treatment for non-HCC patients included a chemotherapy pre-regimen (red dashed line).CC BY-NC-ND · PubMed Central
Figure 2. CART-133 cell dose escalation. (A) Dose group and CART-133 infusion cell dose pattern in all patients. (B) Hemoglobin (Hgb), reticulocyte, CD133+ cells and CAR-gene copy numbers in PB were detected before and at serial time points after CART-133 cell infusion in each patient from every cohort. (C) Tumor biomarkers in serum from each patient were detected before and at serial time points after CART-133 cell infusion. The blue dashed line on the plots is the normal range of each tumor biomarker. Red represents the increase, and green represents the decrease. N = cell infusion cycle; n = case number.
Figure 2. CART-133 cell dose escalation. (A) Dose group and CART-133 infusion cell dose pattern in all patients. (B) Hemoglobin (Hgb), reticulocyte, CD133+ cells and CAR-gene copy numbers in PB were detected before and at serial time points after CART-133 cell infusion in each patient from every cohort. (C) Tumor biomarkers in serum from each patient were detected before and at serial time points after CART-133 cell infusion. The blue dashed line on the plots is the normal range of each tumor biomarker. Red represents the increase, and green represents the decrease. N = cell infusion cycle; n = case number.CC BY-NC-ND · PubMed Central
Figure 3. Safety of CART-133 cells. Cytokines from the serum of each patient's PB, which was collected before and at serial time points after cell infusion, was measured by fluorescence-activated cell sorting. The color shades represent different fold-changes with the baseline.
Figure 3. Safety of CART-133 cells. Cytokines from the serum of each patient's PB, which was collected before and at serial time points after cell infusion, was measured by fluorescence-activated cell sorting. The color shades represent different fold-changes with the baseline.CC BY-NC-ND · PubMed Central
Figure 4. Response of CART-133 cells. (A) Maximum reduction in target lesion size after CART-133 cell infusion. PD: progressive disease, SD: stable disease, PR: partial remission. (B) Progression-free survival and overall survival by the Kaplan-Meier method. (C) Patients were divided into 3 groups based on response from the first cell infusion. PR + SD (lesion-regression), SD (lesion-progression), PD (progressive disease). Statistical analysis of PFS differences between the 3 groups.
Figure 4. Response of CART-133 cells. (A) Maximum reduction in target lesion size after CART-133 cell infusion. PD: progressive disease, SD: stable disease, PR: partial remission. (B) Progression-free survival and overall survival by the Kaplan-Meier method. (C) Patients were divided into 3 groups based on response from the first cell infusion. PR + SD (lesion-regression), SD (lesion-progression), PD (progressive disease). Statistical analysis of PFS differences between the 3 groups.CC BY-NC-ND · PubMed Central
Figure 5. Special presentations. (A) Immunohistochemical examination (diaminobenzidine with hematoxylin counterstaining) of a punch biopsy of liver lesion from patient 12 before and 41 weeks after the first CART-133 cell infusion. (B) Immunohistochemical examination of patient 14 before and 30 weeks after the first CART-133 cell infusion showed that tumor cells were CD133- after cell infusion. Notably, scattered CD3+ and CD8+ cells infiltrated the tumor after infusion, and CD34+ cells significantly decreased. (C) Left: Representative tumor response images for patient 15 before and after CART-133 cell infusion, contrast-enhanced MRI scans show pancreas and liver lesions reduced significantly 4 weeks after the first CART-133 cell infusion and remained reduced after the second cell infusion. Right: CD133+ cells in PB, CAR-gene copy numbers in PB and cytokines in serum were detected before and at serial time points after CART-133 cell infusion in patient 15.
Figure 5. Special presentations. (A) Immunohistochemical examination (diaminobenzidine with hematoxylin counterstaining) of a punch biopsy of liver lesion from patient 12 before and 41 weeks after the first CART-133 cell infusion. (B) Immunohistochemical examination of patient 14 before and 30 weeks after the first CART-133 cell infusion showed that tumor cells were CD133- after cell infusion. Notably, scattered CD3+ and CD8+ cells infiltrated the tumor after infusion, and CD34+ cells significantly decreased. (C) Left: Representative tumor response images for patient 15 before and after CART-133 cell infusion, contrast-enhanced MRI scans show pancreas and liver lesions reduced significantly 4 weeks after the first CART-133 cell infusion and remained reduced after the second cell infusion. Right: CD133+ cells in PB, CAR-gene copy numbers in PB and cytokines in serum were detected before and at serial time points after CART-133 cell infusion in patient 15.CC BY-NC-ND · PubMed Central
Figure 6. Biological evidence of CART-133 cells. (A) Quantitative real-time PCR was performed on genomic DNA harvested from each patient's PB mononuclear cells collected before and at serial time points after CART-133 cell infusion, using primers specific for the transgene. CD133+ cells count change from baseline in the blood after the infusion of CART-133 cells in 21 patients. CART-133 cell infusion in cohort 1 with * is shown. (B) CAR-gene copy numbers analysis from 22 patients (except patient 11, who refused to offer blood for detection) before and during the 1 month after cell infusion; the number of CART-133 cell infusion cycle was 41. (C) Patients were divided into 4 groups based on time of duration of PFS.
Figure 6. Biological evidence of CART-133 cells. (A) Quantitative real-time PCR was performed on genomic DNA harvested from each patient's PB mononuclear cells collected before and at serial time points after CART-133 cell infusion, using primers specific for the transgene. CD133+ cells count change from baseline in the blood after the infusion of CART-133 cells in 21 patients. CART-133 cell infusion in cohort 1 with * is shown. (B) CAR-gene copy numbers analysis from 22 patients (except patient 11, who refused to offer blood for detection) before and during the 1 month after cell infusion; the number of CART-133 cell infusion cycle was 41. (C) Patients were divided into 4 groups based on time of duration of PFS.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Kochenderfer JN, 2017, J Clin Oncol, JCO2016713024

Cited by

See all 341

Metadata

Authors
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., Feng, K.-C., Yang, Q.-M., Li, X.-L., & Han, W.
Affiliations
  • Chinese PLA General Hospital (CN)
  • Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing, China
  • Department of Molecular & Immunology, Chinese PLA General Hospital, Beijing, China
Corresponding author
Han, Weidong
Venue
OncoImmunology
Published
2018-05-07
Volume
7
Issue
7
Pages
e1440169
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2790863559
Cited by
338
References
42
Citations by year
2026: 25 · 2025: 37 · 2024: 50 · 2023: 48 · 2022: 57 · 2021: 47 · 2020: 39 · 2019: 26 · 2018: 9
FWCI
11.37
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • OncoImmunology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Developement Program of Chinas (2016YFC1303501 2016YFC1303504)
  • Science and Technology Planning Project of Beijing City (Z151100003915076)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
CD133, chimeric antigen receptor T cells, CAR T-cell therapy, cancer stem cells, hepatocellular carcinoma, pancreatic cancer, colorectal cancer, metastatic cancer, dose escalation, hematologic toxicity, disease control rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. https://app.cochat.ai/papers/10.1080/2162402x.2018.1440169
The paper
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., Feng, K.-C., Yang, Q.-M., Li, X.-L., & Han, W. (2018). CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1440169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.